Head-to-head evidence
ALZ-101 vs Remternetug
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: Amyloid-beta (monoclonal antibody) · full Alzheimer's Disease pipeline
ALZ-101
Developed by Alzinova AB
NCT05328115 · Phase 1 · completed
Most of the trial was randomized and blinded against placebo, but the highest-dose group was given openly rather than blinded, and only 33 people took part. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reports Part A of the trial (26 randomised participants), fewer than the trial's registered enrollment of 33.
Remternetug
Developed by Eli Lilly
NCT05463731 · Phase 3 · completed
The study randomized 1,667 participants to remternetug or matching placebo, with participants and investigators blinded during the main treatment period. Its primary endpoint was amyloid plaque clearance measured by PET, a biomarker endpoint, and the registry does not report whether the week-52 comparison was favorable or statistically significant.
Next expected readout: April 2029 · NCT06653153 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALZ-101's landscape · Remternetug's landscape